David Fernandez-Antoran

Group leader

Research summary

Radiation biology and cell competition

Healthy adult epithelial tissues progressively accumulate clones of cells carrying mutations implicated in cancer and their expansion follows Darwinian evolution rules. Some mutations can increase cell fitness and promote the growth of clones at the expenses of the non-mutated normal adjacent cells, in a process of clonal competition.

Ionising radiation has long been studied as one of the most common environmental mutagenic agents that promotes tumour formation by damaging DNA and creating new oncogenic mutations. However, little is known about its effects on cell competition, clonal evolution and tissue dynamics.

Expand summary

We have recently shown that it can act as a selective pressure, affecting cell competition mechanisms and promoting selection of pre-existing oncogenic mutations, which might affect field cancerisation and increase the risk of cancer development in the future.

We use long-term human and mouse 3D primary epithelial cultures, in vivo cell lineage tracing, mathematical modelling, next generation sequencing methods and state-of-the-art confocal microscopy techniques to unravel the molecular responses and the cellular interactions that control normal and mutant cell behaviours after exposure to different doses of ionising radiation.

The final aim of our research is to understand the effects of ionising radiation in tumours and normal tissues and set the basis for designing external interventions that can modulate cell competition outcomes, eliminate oncogenic mutations from tissues and reduce the risk of cancer initiation and progression.

Rendered image of cells in irradiated mouse oesophageal epithelium

The fight for space during ionising radiation exposure. This rendered image shows an irradiated mouse oesophageal epithelium populated by fitter oncogenic mutant clones (green) that are expanding at the expense of non-mutated normal adjacent cells. Proliferation markers are shown in white and red; cell nuclei in blue.

David Fernandez-Antoran colour portrait

Selected publications

  • Colom B et al. (2021) Mutant clones in normal epithelium outcompete and eliminate emerging tumours. Nature 598: 510–514. DOI: 10.1038/s41586-021-03965-7.

    October 13, 2021

    Read more
  • Fowler JC et al. (2021) Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site. Cancer Discovery DOI: 10.1158/2159-8290.CD-20-1092.

    February 1, 2021

    Read more
  • Piedrafita G et al. (2020) A single-progenitor model as the unifying paradigm of epidermal and esophageal epithelial maintenance in mice. Nature Communications 11: 1429. DOI: 10.1038/s41467-020-15258-0.

    March 18, 2020

    Read more
  • Fernandez-Antoran D et al. (2019) Outcompeting p53-mutant cells in the normal esophagus by redox manipulation. Cell Stem Cell 25: P329-341.E6. DOI: 10.1016/j.stem.2019.06.011.

    July 18, 2019

    Read more
  • Martincorena I et al. (2018) Somatic mutant clones colonize the human esophagus with age. Science 362: 911-917. DOI: 10.1126/science.aau3879

    November 23, 2018

    Read more

Biography

David Fernandez-Antoran PhD, CRUK-RadNet Group Leader, Member of the University Department of Pathology

I did my PhD in Immunology at the Spanish National Centre for Biotechnology (CNB-Madrid), where I studied the role of the proto-oncogene c-myc and its partner max in the development and maturation of B-lymphocytes in vivo.

In 2013 I started a postdoctoral position in the laboratory of Prof. Philip H. Jones (MRC-Cancer Unit / University of Cambridge and The Sanger Institute), funded by European Radiation Agency, where I developed a profound knowledge of epithelial tissue architecture, cell behaviour, radiation biology and cancer development. I studied how epithelial progenitor cells respond to environmental factors like low doses of ionising radiation and how this affects clonal competition within healthy tissues. I demonstrated that these exposures promote the expansion of oncogenic mutations in the oesophageal epithelium. I also demonstrated for the first time how to interfere with this process and deplete mutant cells by manipulating redox status, which opens a new field of study for future interventions in humans in order to reduce cancer risk.

In collaboration with colleagues from The Sanger and Wellcome Stem Cell Institutes, I developed and optimized a new model of in vitro long-term and self-maintaining 3D primary culture using mouse and human epithelial tissues. This system affords a novel concept in the field and allows long-term studies on tissue regeneration, cell-to-cell dynamic interactions, drug responses as well as monitoring early steps of tumour development in vitro.

I started my own laboratory, funded by CRUK-RadNet, at The Gurdon Institute in 2020. Our aim is to understand how radiotherapy treatments (among other environmental factors), modulate cell competition mechanisms in different epithelia, by introducing new selective pressures that change the mutational landscape and might affect tissue function and promote carcinogenesis.

Notable achievements and honours

  • 2022
    CRUK–RadNet Seed funding for FLASH radiotherapy studies
  • 2022
    NC3Rs–CRUK Skills and Knowledge Transfer grant
  • 2022
    Co-Chair CRUK–RadNet Emerging Radiotherapies Technologies
  • 2022
    CRUK–RadNet Infrastructure grant
  • 2021
    Isaac Newton Trust / Wellcome Trust ISSF / University of Cambridge Joint Research Grants Scheme
  • 2020
    CRUK–RadNet Grant
  • 2013
    RISK - IR GRANT. FP7-EURATOM-FISSION

Research group

  • Ines Ferreira

    PhD Student

  • Michelle Miniter

    Research Assistant/ Lab Manager

  • Dr Jose Valverde Lopez

    Research Associate